Program
ceralasertib
Also written as “Ceralasertib”, “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).” and “[14C] AZD6738”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell · Melanoma, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 167 open or running | phase 3since Jul 6, 2022 | Sep 30, 2013 | none ahead |
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 30, 2013.
- Jan 13, 2017Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT03022409 · 21 enrolled · United States, France, Taiwan
- Sep 22, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03334617 · 528 enrolled · United States, Austria, Canada and more
- Oct 16, 2017Phase 2 study in Triple Negative Breast NeoplasmsNCT03330847 · 273 enrolled · United States, Belgium, Canada and more
- Oct 30, 2017Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03328273 · 12 enrolled · Poland, United Kingdom
- Apr 24, 2018Phase 1 study in Lymphoma, Non-HodgkinNCT03527147 · 30 enrolled · United States, United Kingdom
- Jan 21, 2020Phase 2 study in Ovarian NeoplasmsNCT04239014 · United States, Canada, Italy and more
- Sep 8, 2020Phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT04564027 · 54 enrolled · United States, France, Spain
- Sep 22, 2021Phase 2 study in MelanomaNCT05061134 · 194 enrolled · United States, Australia, Belgium and more
- May 18, 2022Phase 1 study in Advanced Solid MalignanciesNCT05469919 · 12 enrolled · Japan
- Jul 6, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05450692 · 594 enrolled · United States, Argentina, Australia and more
- Aug 23, 2022Phase 1 study in Advanced Solid TumoursNCT05514132 · 14 enrolled · China
- Jun 12, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05941897 · 39 enrolled · Russia
- Nov 4, 2024Phase 1 study in NeoplasmsNCT06754761 · 2 enrolled · United Kingdom
- Apr 14, 2025Phase 1 study in Advanced Solid TumoursNCT06929260 · 1 enrolled · United Kingdom
TargetBeta
“An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, ”NCIt, by rule
“Serine-protein kinase ATR inhibitor”ChEMBL 37, by rule
Other programs on ATR
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06929260Advanced Solid Tumours · United Kingdom | 1 | Terminated | Oct 15, 2025 | 1 |
| NCT06754761Neoplasms · United Kingdom | 1 | Terminated | Oct 21, 2025 | 2 |
| NCT05941897Carcinoma, Non-Small-Cell Lung · Russia | 2 | Active, not recruiting | Jul 29, 2024 | 39 |
| NCT05514132Advanced Solid Tumours · China | 1 | Active, not recruiting | Oct 20, 2023 | 14 |
| NCT05450692Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 6, 2025 | 594 |
| NCT05469919Advanced Solid Malignancies · Japan | 1 | Completed | Aug 17, 2023 | 12 |
| NCT05061134Melanoma · United States, Australia, Belgium and more | 2 | Active, not recruiting | Apr 12, 2024 | 194 |
| NCT04564027Hereditary Sensory and Autonomic Neuropathies · United States, France, Spain | 2 | Completed | Feb 18, 2025 | 54 |
| NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more | 2 | Withdrawn | Jan 25, 2021 | 0 |
| NCT03527147Lymphoma, Non-Hodgkin · United States, United Kingdom | 1 | Completed | Mar 31, 2021 | 30 |
| NCT03328273Leukemia, Lymphocytic, Chronic, B-Cell · Poland, United Kingdom | 1 | Active, not recruiting | Sep 7, 2021 | 12 |
| NCT03330847Triple Negative Breast Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Nov 13, 2020 | 273 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | Sep 13, 2024 | 528 |
| NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan | 1 | Completed | Jan 20, 2021 | 21 |
| NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more | 2 | Completed | Jun 22, 2020 | 72 |
| NCT01955668Leukemia, B-Cell · United States | 1 | Completed | Dec 2013 | 2 |
How it is read
Names in the registry
- “Ceralasertib”, 11 entries
- “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).”, 1 entry
- “[14C] AZD6738”, 1 entry
- “AZD6738 / ceralasertib”, 1 entry
- “AZD6738 and olaparib”, 1 entry
Codes read as this program: AZD6738.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Triple Negative Breast Neoplasms, 1 study
- Neoplasms, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.